The NIH Stroke Scale Has Limited Utility in Accurate Daily Monitoring of Neurologic Status
- 13 December 2015
- journal article
- research article
- Published by SAGE Publications in The Neurohospitalist
- Vol. 6 (3), 97-101
- https://doi.org/10.1177/1941874415619964
Abstract
Background and Purpose: The National Institute of Health Stroke Scale (NIHSS) is rapid and reproducible, a seemingly attractive metric for the documentation of clinical progress in patients presenting with ischemic stroke. Many institutions have adopted it into daily clinical practice. Unfortunately, the scale may not adequately capture all forms of functional change. We evaluate its utility as a measure of recovery in patients treated with intravenous tissue plasminogen activator (IV tPA) for ischemic stroke. Methods: We prospectively evaluated the difference in the rate of improvement based on NIHSS (a ≥4 point change based on previous trials) versus physician-documented subjective and objective measures in 41 patients’ status post IV tPA treatment. The NIHSS 24 hours posttreatment, on discharge, and at follow-up were compared to NIHSS on admission using tests of proportions and McNemar tests of paired data. Secondary analyses were performed defining significant improvement as NIHSS changes of 1 to 3 points. Results: The mean NIHSS improved from 9 to 6, 24 hours post-tPA. Of the 41 patients, 29 improved by physician documentation, although only 11 of the 29 met the NIHSS criteria ( P < .001; McNemar P < .001). On discharge, 20 of the 41 patients met the NIHSS criteria; however, the proportion “better” by physician documentation (71%) remained significantly higher ( P = .04; McNemar P = .004). The mean postdischarge follow-up NIHSS was 2. Twenty of the 21 patients improved by documentation versus 16 of the 21 by NIHSS ( P = .08, McNemar P = .125). Using NIHSS changes of 1 to 3 increased sensitivity for detecting improvement but remained lower than physician documentation. Conclusion: The NIHSS has many advantages; however, it may miss functional changes when used in place of a comprehensive neurological examination to measure improvement poststroke.Keywords
This publication has 14 references indexed in Scilit:
- A Trial of Imaging Selection and Endovascular Treatment for Ischemic StrokeNew England Journal of Medicine, 2013
- Endovascular Therapy after Intravenous t-PA versus t-PA Alone for StrokeNew England Journal of Medicine, 2013
- Neuropsychological outcome after a first symptomatic ischaemic stroke with ‘good recovery’European Journal of Neurology, 2011
- The NIHSS-Plus: Improving Cognitive Assessment with the NIHSSBehavioural Neurology, 2010
- The Modified National Institutes of Health Stroke Scale: its Time has ComeInternational Journal of Stroke, 2009
- Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trialThe Lancet Neurology, 2008
- Acute Stroke Care in the USStroke, 2005
- Risk Factors for Severe Hemorrhagic Transformation in Ischemic Stroke Patients Treated With Recombinant Tissue Plasminogen ActivatorStroke, 2001
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995
- Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.Stroke, 1993